Hologic, Inc. $HOLX Position Trimmed by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 38.5% during the second quarter, Holdings Channel.com reports. The firm owned 15,034 shares of the medical equipment provider’s stock after selling 9,431 shares during the period. Texas Permanent School Fund Corp’s holdings in Hologic were worth $980,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Chung Wu Investment Group LLC purchased a new position in Hologic during the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares during the period. Loomis Sayles & Co. L P purchased a new position in shares of Hologic during the 2nd quarter valued at $33,000. Cromwell Holdings LLC increased its stake in shares of Hologic by 307.0% in the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 436 shares during the last quarter. Finally, CYBER HORNET ETFs LLC purchased a new stake in shares of Hologic during the second quarter worth $40,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.88% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. BTIG Research restated a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Stephens cut Hologic from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $78.00 to $76.00 in a research note on Wednesday, October 22nd. Argus raised their price objective on shares of Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Finally, Mizuho lowered shares of Hologic from an “outperform” rating to a “neutral” rating and increased their price target for the stock from $70.00 to $78.00 in a research note on Thursday, October 23rd. Five investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $79.29.

Hologic Stock Down 0.2%

Shares of Hologic stock opened at $74.70 on Thursday. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.34. The company has a quick ratio of 3.06, a current ratio of 3.75 and a debt-to-equity ratio of 0.50. The stock has a 50 day moving average price of $74.24 and a two-hundred day moving average price of $69.01. The stock has a market capitalization of $16.65 billion, a P/E ratio of 30.12, a PEG ratio of 2.12 and a beta of 0.70.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.01 earnings per share. Equities analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.